C
Clemens M. Wendtner
Researcher at Ludwig Maximilian University of Munich
Publications - 118
Citations - 16544
Clemens M. Wendtner is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Chronic lymphocytic leukemia & Fludarabine. The author has an hindex of 37, co-authored 106 publications receiving 13614 citations. Previous affiliations of Clemens M. Wendtner include University of Calgary & University of Bonn.
Papers
More filters
Posted ContentDOI
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
Alina Tscherne,Jan Hendrik Schwarz,Cornelius Rohde,Alexandra Kupke,Georgia Kalodimou,Leonard Limpinsel,Nisreen M.A. Okba,Berislav Bošnjak,Inga Sandrock,Sandro Halwe,Lucie Sauerhering,Katrin Printz,Liangliang Nan,Elke R. Duell,Sylvia Jany,Astrid Freudenstein,Joerg C. Schmidt,Anke Werner,Michelle Gellhorn,Michael Kluever,Wolfgang Guggemos,M Seilmaier,Clemens M. Wendtner,Reinhold Foerster,Bart L. Haagmans,Stephan Becker,Gerd Sutter,Asisa Volz,Asisa Volz +28 more
TL;DR: In this paper, the authors describe the construction and preclinical characterization of a recombinant MVA expressing full-length SARS-CoV-2 spike (S) protein (MVA-SARS-2-S).
Journal ArticleDOI
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*
Clemens M. Wendtner,Michael Hallek,Graeme Fraser,Anne Sophie Michallet,Peter Hillmen,Jan Dürig,Matt Kalaycio,John G. Gribben,Stephan Stilgenbauer,Andreas Bühler,Thomas J. Kipps,Brendan Purse,Jennie Zhang,Sabine De Bedout,Jay Mei,Asher Chanan-Khan +15 more
TL;DR: Lower starting doses allowed subsequent dose escalation of lenalidomide while maintaining an acceptable tolerability profile in patients with relapsed/refractory CLL.
Journal ArticleDOI
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
Billy Michael Chelliah Jebaraj,Eugen Tausch,Dan A. Landau,Jasmin Bahlo,Sandra Robrecht,Amaro Taylor-Weiner,Johannes Bloehdorn,Annika Scheffold,Daniel Mertens,Sebastian Böttcher,Michael Kneba,Ulrich Jäger,Thorsten Zenz,Thorsten Zenz,Michael Wenger,Guenter Fingerle-Rowson,Clemens M. Wendtner,Anna-Maria Fink,Catherine J. Wu,Barbara Eichhorst,Kirsten Fischer,Michael Hallek,Hartmut Döhner,Stephan Stilgenbauer +23 more
TL;DR: Aside from identifying associations of short telomere length with adverse prognostic factors and survival, the study identified cases with 17p- and 11q- associated with TP53 and ATM loss, respectively, to have the shortest telomeres, even when these aberrations were present in small subclones.
Journal Article
Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil Interim analysis of a phase III study of the German CLL Study Group
Barbara Eichhorst,Raymonde Busch,Martina Stauch,Michael Kneba,Matthias Ritgen,Ulrike Soeling,Oswald Burkhard,Manuela Bergmann,Clemens M. Wendtner,Wolfgang Hiddemann,Bertold Emmerich,Michael Hallek,Gcllsg +12 more
Journal ArticleDOI
Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)
Anna-Maria Fink,Jasmin Bahlo,Robrecht Sandra,Othman Al-Sawaf,Ali Aldaoud,Holger Hebart,Kathleen Jentsch-Ulrich,Steffen Doerfel,Kirsten Fischer,Clemens M. Wendtner,Thomas Noesslinger,Paolo Ghia,Francesc Bosch,Arnon P. Kater,Karl-Anton Kreuzer,Hartmut Döhner,Michael Kneba,Stephan Stilgenbauer,Sebastian Boettcher,Barbara Eichhorst,Michael Hallek +20 more
TL;DR: Lenalidomide is a feasible and efficacious maintenance option for highrisk CLL after chemoimmunotherapy and substantially prolonged PFS in high risk CLL patients resulting in a relative risk reduction for progression of more than 80%.